These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23620557)

  • 1. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein.
    Moncrieffe H; Ursu S; Holzinger D; Patrick F; Kassoumeri L; Wade A; Roth J; Wedderburn LR
    Rheumatology (Oxford); 2013 Aug; 52(8):1467-76. PubMed ID: 23620557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L; Ricci L; Zulian F; Del Monte F; Simonini G; Capannini S; De Martino M; Brandi ML; Falcini F
    J Rheumatol; 2009 Oct; 36(10):2308-13. PubMed ID: 19684155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K; Ortiz-Alvarez O; Cabral DA; Tucker LB; Petty RE; Malleson PN
    J Rheumatol; 2004 Jan; 31(1):179-82. PubMed ID: 14705239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis.
    Viswanath V; Myles A; Dayal R; Aggarwal A
    J Rheumatol; 2011 Nov; 38(11):2482-7. PubMed ID: 21885500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations.
    Becker ML; van Haandel L; Gaedigk R; Lasky A; Hoeltzel M; Stobaugh J; Leeder JS
    Arthritis Rheum; 2010 Jun; 62(6):1803-12. PubMed ID: 20191581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis.
    Schmeling H; Biber D; Heins S; Horneff G
    J Rheumatol; 2005 Sep; 32(9):1832-6. PubMed ID: 16142884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.
    Albers HM; Wessels JA; van der Straaten RJ; Brinkman DM; Suijlekom-Smit LW; Kamphuis SS; Girschick HJ; Wouters C; Schilham MW; le Cessie S; Huizinga TW; Ten Cate R; Guchelaar HJ
    Arthritis Rheum; 2009 Jan; 61(1):46-51. PubMed ID: 19116975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I
    Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis.
    Ortiz-Alvarez O; Morishita K; Avery G; Green J; Petty RE; Tucker LB; Malleson PN; Cabral DA
    J Rheumatol; 2004 Dec; 31(12):2501-6. PubMed ID: 15570658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
    Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
    Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry.
    Klein A; Kaul I; Foeldvari I; Ganser G; Urban A; Horneff G
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1349-56. PubMed ID: 22649024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
    Ruperto N; Murray KJ; Gerloni V; Wulffraat N; de Oliveira SK; Falcini F; Dolezalova P; Alessio M; Burgos-Vargas R; Corona F; Vesely R; Foster H; Davidson J; Zulian F; Asplin L; Baildam E; Consuegra JG; Ozdogan H; Saurenmann R; Joos R; Pistorio A; Woo P; Martini A;
    Arthritis Rheum; 2004 Jul; 50(7):2191-201. PubMed ID: 15248217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.
    de Thurah A; Nørgaard M; Johansen M; Stengaard-Pedersen K
    Scand J Rheumatol; 2010; 39(1):19-25. PubMed ID: 20132066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.
    Bulatovic M; Heijstek MW; Van Dijkhuizen EH; Wulffraat NM; Pluijm SM; de Jonge R
    Ann Rheum Dis; 2012 Sep; 71(9):1484-9. PubMed ID: 22473625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations.
    Foell D; Wittkowski H; Hammerschmidt I; Wulffraat N; Schmeling H; Frosch M; Horneff G; Kuis W; Sorg C; Roth J
    Arthritis Rheum; 2004 Apr; 50(4):1286-95. PubMed ID: 15077313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
    van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
    Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis.
    Ravelli A; Di Fuccia G; Molinaro M; Ramenghi B; Zonta L; Regazzi MB; Martini A
    J Rheumatol; 1993 Sep; 20(9):1573-7. PubMed ID: 8164218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis.
    Bartoli M; Tarò M; Magni-Manzoni S; Pistorio A; Traverso F; Viola S; Magnani A; Gasparini C; Martini A; Ravelli A
    Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.